Deerfield
VC Fund
New York, United States
Deerfield is an investment management firm. They provide a healthcare ecosystem through information and investment. They also provide private and public investments across the life science, medical device, diagnostic, digital health, and health service industries.
- Total investments:
- 285
- Last investment:
- Lead investor:
- 41%
- Fund size:
- $600M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Deerfield invests in
Stages Deerfield invests in
Countries Deerfield invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 14 contacts → | |||
Round size
- Series A
- $11M–$67M
- Series B
- $30M–$114M
- Series C
- $20M–$110M
Investment Focus
Industry
- Health Care 136 (48%)
- Biotechnology 130 (46%)
- Medical 75 (26%)
- Pharmaceutical 56 (20%)
- Therapeutics 52 (18%)
Stage
- Series A 39 (14%)
- Series C 39 (14%)
- Series B 35 (12%)
- Venture - Series Unknown 35 (12%)
- Post-IPO Equity 27 (9%)
Country
- United States 179 (63%)
- United Kingdom 6 (2%)
- Canada 3 (1%)
- France 3 (1%)
- Israel 3 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Alexander Karnal
Partner and Managing Director
|
Partner and Managing Director | Total investments: 0 | Find email | |
Andrew ElBardissi
Partner
|
Partner | Total investments: 14 | Find email | |
Bryan Sendrowski
Partner
|
Partner | Total investments: 0 | Find email | |
Cameron Wheeler
Principal
|
Principal | Total investments: 20 | Find email | |
Elise Wang
Partner, Head of Private Equity Capital Markets
|
Partner, Head of Private Equity Capital Markets | Total investments: 5 | Find email | |
| See all 14 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Neomorph
|
Neomorph is building a leading protein degradation entity, focused on “molecular glue” degraders. Its mission is to use this technology to solve critical problems in human health with the discovery and development of innovative new medicines against “undruggable targets.” | $100M / Series B / Apr 13, 2026 | |
SHINE Technologies
|
SHINE Medical Technologies, Inc. manufactures and supplies medical tracers and cancer treatment elements. The company offers Molybdenum-99, a light-emitting element that is administered to patients for the purpose of diagnosing and staging cancer and heart diseases. It also provides Iodine-131 that is used to treat thyroid cancer and variousabnormal thyroid conditions, including hyperthyroidism, as well as to diagnose liver function, renal blood flow, and urinary tract obstruction.The company was founded in 2010 and is headquartered in Janesville, Wisconsin. | $240M / Series E / Feb 26, 2026 | |
Axon Therapies
|
Develops a healthcare device with a neuromodulation approach to treat heart failure. | $32M / Series A / Sep 25, 2025 | |
BBOT
|
BridgeBio Oncology Therapeutics operates as a biopharmaceutical company. | $261M / Post-IPO Equity / Aug 11, 2025 | |
Bluefin BioMedicine
|
Bluefin BioMedicine develops medicines for the treatment of cancer. | Venture - Series Unknown / Jul 01, 2025 | |
The Oncology Institute of Hope and Innovation
|
The Oncology Institute of Hope and Innovation is one of the largest community oncology practices in the U.S. as well as our nation’s leading value-based oncology services platform. The Oncology Institute provides care through more than 80 physicians and advanced practice providers in 50+ clinic locations, with more than 500 total employees helpingto offer leading-edge, evidence-based cancer care to a population of more than 1 million patients. The Oncology Institute brings comprehensive, integrated cancer care into community settings, including clinical trials, stem cell transplants, transfusions, and other care delivery models traditionally associated with the most advanced tertiary care settings. | $16.5M / Post-IPO Equity / Mar 24, 2025 | |
LiquidXR
|
LiquidXR is a developer of an AI and ML-powered wearable motion-tracking platform designed to enable ergonomic, real-time body-based interaction in extended reality environments. The company provides rugged, washable, and affordable motion capture lightweight gloves, insoles, and other wearables that are built with stretchable electronics thateliminate wires, cameras, and line of sight constraints, enabling sports trainers and gamers to have a location-based XR entertainment experience. | Seed / Nov 01, 2024 | |
Day One Biopharmaceuticals
|
Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages. The company understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine. They develop new therapies that meet the critical needs of peopleof all ages living with cancer starting from the biology of childhood cancer.Day One Biopharmaceuticals also focuses its efforts to bring the best medicines to families receiving the life-altering news of a new cancer diagnosis and the need for a treatment plan. It prioritizes programs that can be rapidly brought to market for both younger and older patients. The company's goal is to license and acquire the most promising products from research institutions as well as for biotechnology and pharmaceutical companies.Day One Biopharmaceuticals was founded in 2018 and is headquartered in South San Francisco, CA, USA. | $175M / Post-IPO Equity / Jul 30, 2024 | |
Advanced Medicine Partners
|
Advanced Medicine Partners is a biotechnology company that specializes in viral vector manufacturing for genes and cells. | $32M / Series A / Jun 05, 2024 | |
|
Advanced Medicine Partners
|
Advanced Medicine Partners is a biotechnology company that specializes in viral vector manufacturing for genes and cells. | $32M / Series A / Jun 05, 2024 | |
| See all 285 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Deerfield invest in?
Deerfield invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series C stage. Most of the 285 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Deerfield's check size?
Deerfield typically joins rounds of $11M–$67M at Series A, $30M–$114M at Series B and $20M–$110M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Deerfield participates in.
How do I contact Deerfield?
Public channels for Deerfield include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Deerfield?
The team at Deerfield includes Alexander Karnal (Partner and Managing Director), Andrew ElBardissi (Partner) and Bryan Sendrowski (Partner), among 14 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
